After a string of mid-stage failures this year, plus a blow to its major depression commercial plans last year, Sage ...

Novartis is spending $70 million upfront on a small molecule antitumor drug from the Chinese biotech Chengdu Baiyu. The Swiss ...

The Alliance for Pharmacy Compounding (APC) wants clarity around the FDA’s decision to reconsider tirzepatide’s removal from ...

Bavarian Nordic’s mpox vaccine Jynneos generated a similar immune response in adolescents as it did in adults, offering ...

An experimental therapy designed to change a single letter of short-lived mRNA molecules has corrected a genetic mutation ...

Novavax’s post-Covid path ran into a speed bump Wednesday, as the company announced a clinical hold on its Covid-influenza ...

Investors have been placing bets into startups that help members of low-income households on Medicaid insurance get care. A ...

Starboard Value may have lost its first skirmish with Pfizer. But the activist investor has a track record of protracted, ...

Plus, news about TenNor Therapeutics, Gan & Lee Pharmaceuticals, Orasis and Optus Pharmaceuticals: Exscientia receives $15M milestone from Sanofi: The companies are advancing two programs as ...

Neurogastrx believes its drug could treat one of the most troublesome side effects of one of the industry's biggest ...

Takeda will not move forward with Wave Life Sciences on a Huntington’s disease drug, ending their collaboration that first ...

Almost a year ago, Sanofi made history for the wrong reasons. Last October, CEO Paul Hudson announced strategic changes ...